$0.21 EPS Expected for Medidata Solutions Inc (NASDAQ:MDSO) This Quarter
Equities analysts predict that Medidata Solutions Inc (NASDAQ:MDSO) will post earnings per share of $0.21 for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for Medidata Solutions’ earnings, with the highest EPS estimate coming in at $0.23 and the lowest estimate coming in at $0.20. Medidata Solutions also reported earnings per share of $0.21 during the same quarter last year. The company is expected to announce its next quarterly earnings results on Thursday, October 17th.
According to Zacks, analysts expect that Medidata Solutions will report full-year earnings of $0.78 per share for the current year, with EPS estimates ranging from $0.73 to $0.83. For the next fiscal year, analysts forecast that the firm will report earnings of $1.07 per share, with EPS estimates ranging from $0.96 to $1.22. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Medidata Solutions.
Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings results on Monday, July 22nd. The company reported $0.48 EPS for the quarter, beating the Zacks’ consensus estimate of $0.17 by $0.31. The business had revenue of $180.50 million for the quarter, compared to analyst estimates of $179.95 million. Medidata Solutions had a net margin of 6.43% and a return on equity of 8.64%. Medidata Solutions’s quarterly revenue was up 15.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.43 EPS.
Several institutional investors have recently added to or reduced their stakes in MDSO. Dimensional Fund Advisors LP lifted its stake in shares of Medidata Solutions by 55.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 224,308 shares of the company’s stock valued at $15,122,000 after buying an additional 80,395 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Medidata Solutions by 9.4% during the fourth quarter. Geode Capital Management LLC now owns 677,455 shares of the company’s stock valued at $45,674,000 after purchasing an additional 58,069 shares in the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of Medidata Solutions by 1,155.8% during the first quarter. BNP Paribas Arbitrage SA now owns 12,131 shares of the company’s stock valued at $888,000 after purchasing an additional 11,165 shares in the last quarter. Bank of Montreal Can lifted its position in shares of Medidata Solutions by 11.9% during the first quarter. Bank of Montreal Can now owns 6,170 shares of the company’s stock valued at $453,000 after purchasing an additional 658 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its position in shares of Medidata Solutions by 126.8% during the first quarter. Quadrant Capital Group LLC now owns 592 shares of the company’s stock valued at $40,000 after purchasing an additional 331 shares in the last quarter. 91.31% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Medidata Solutions stock traded up $0.07 on Monday, reaching $91.79. 9,483 shares of the stock were exchanged, compared to its average volume of 569,920. The firm’s 50 day moving average is $91.47 and its 200-day moving average is $86.74. Medidata Solutions has a one year low of $60.10 and a one year high of $98.60. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.56 and a current ratio of 2.56. The firm has a market cap of $5.73 billion, a PE ratio of 95.60, a P/E/G ratio of 6.19 and a beta of 1.23.
About Medidata Solutions
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.
Featured Story: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.